New director joins IDT (NYSE: IDT) board to lead audit oversight
Filing Impact
Filing Sentiment
Form Type
8-K
Rhea-AI Filing Summary
IDT Corporation reported a board change, with director Irwin Katsof resigning and the board appointing William Conkling as a new independent director. The company stated that Katsof’s resignation was not due to any disagreement over operations, policies, or practices.
Conkling will serve on the board until the 2026 annual meeting and is expected to chair the Audit Committee, act as the Audit Committee Financial Expert, and sit on the Compensation and Corporate Governance Committees. He brings senior commercial and leadership experience from Protara Therapeutics, Rafael Holdings, Immunomedics, and Novartis.
Positive
- None.
Negative
- None.
8-K Event Classification
2 items: 5.02, 9.01
2 items
Item 5.02
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers
Governance
Key personnel changes including departures, elections, or appointments of directors and executive officers.
Item 9.01
Financial Statements and Exhibits
Exhibits
Financial statements, pro forma financial information, and exhibit attachments filed with this report.
Key Figures
Board change date: June 9, 2026
Director age: 55 years
Acquisition value: $21 billion
3 metrics
Board change date
June 9, 2026
Date Katsof resigned and Conkling was appointed
Director age
55 years
Age of new director William Conkling
Acquisition value
$21 billion
Gilead’s October 2020 acquisition of Immunomedics, where Conkling held a senior role
Key Terms
Emerging growth company, Audit Committee Financial Expert, Regulation S-K, Non-Employee Director Compensation Program, +1 more
5 terms
Emerging growth company regulatory
"405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company"
An emerging growth company is a recently public or smaller public firm that qualifies for temporary, lighter regulatory and disclosure rules to reduce the cost and effort of being public. For investors, it means the company may provide less historical financial detail and face fewer reporting requirements than larger firms, so it can grow more quickly but also carries higher uncertainty—like buying a promising early-stage product with fewer user reviews.
Audit Committee Financial Expert financial
"Mr. Conkling is expected to serve as the Chairman of the Audit Committee and be the Audit Committee Financial Expert"
A person on a company’s board who has deep knowledge of accounting, financial reporting and auditing, able to understand and question the books, controls and audit work like a trained mechanic inspecting an engine. Investors care because that expertise helps spot errors, weaknesses or misleading statements early, improving the likelihood that financial reports are accurate and reducing the risk of surprises that can hurt a company’s value.
Regulation S-K regulatory
"material interest in any transaction required to be disclosed pursuant to Item 404(a) of Regulation S-K"
A set of U.S. Securities and Exchange Commission rules that tell public companies which narrative and qualitative details must be disclosed in filings, such as risk factors, management discussion, executive pay, legal proceedings and business description. Think of it as a standardized checklist or blueprint that ensures investors get the same types of background information from every company so they can compare risks, management quality and strategy before making investment decisions.
Non-Employee Director Compensation Program financial
"Mr. Conkling is eligible to participate in the Company’s Non-Employee Director Compensation Program, which provides for annual compensation"
independent regulatory
"The Board has determined that Mr. Conkling is “independent” in accordance with the listing standards of the New York Stock Exchange"
FAQ
What board changes did IDT (IDT) disclose in this Form 8-K?
IDT reported that director Irwin Katsof resigned from the board and its committees, not due to any disagreement. The board simultaneously appointed William Conkling as an independent director, with his term running until the company’s 2026 annual meeting of stockholders.
Why did Irwin Katsof resign from IDT’s board of directors?
IDT stated that Irwin Katsof’s resignation from the board and its committees was not the result of any disagreement with the company’s operations, policies, or practices. This language is commonly used to clarify that no underlying dispute triggered the departure.
Who is William Conkling, the new independent director at IDT (IDT)?
William Conkling is 55 and currently Chief Commercial Officer of Protara Therapeutics Inc. He previously served as CEO of Rafael Holdings, held senior roles at Immunomedics and Novartis, and sits on several healthcare company boards, bringing extensive commercialization and leadership experience.
What committees will William Conkling serve on at IDT Corporation?
William Conkling is expected to chair the Audit Committee, serve as the Audit Committee Financial Expert, and sit on the Compensation Committee and Corporate Governance Committee. These roles position him centrally in IDT’s financial oversight, executive pay, and governance frameworks.
Is William Conkling considered independent under NYSE and SEC rules?
The board determined that William Conkling is independent under New York Stock Exchange listing standards, the company’s internal policies, and applicable SEC rules. This independence status is important for his role as Audit Committee chair and Audit Committee Financial Expert.
Will William Conkling receive compensation as an IDT non-employee director?
Yes. William Conkling is eligible to participate in IDT’s Non-Employee Director Compensation Program. This program provides annual compensation through a mix of cash and equity-based awards, aligning director pay with shareholder interests and customary governance practices.